(Q34545316)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27873300%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

title

Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27873300%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27873300%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

author name string

Luuk van Hooren

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27873300%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Linda C Sandin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27873300%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Igor Moskalev

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27873300%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Peter Ellmark

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27873300%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Peter Black

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27873300%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Thomas H Tötterman

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27873300%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Sara M Mangsbo

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27873300%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

language of work or name

English

0 references

publication date

13 December 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27873300%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Immunology

28 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27873300%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27873300%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

page(s)

385-393

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27873300%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27873300%20AND%20SRC:MED&resulttype=core&format=json

Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy.

28 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

Ipilimumab: first global approval.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

Neoantigens in cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

The mechanism of action of BCG therapy for bladder cancer--a current perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

Immune Checkpoint Blockade in Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

Opportunistic infections in patients treated with immunotherapy for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

Innate and adaptive immune cells in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

Cancer immune contexture and immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201646583

21 January 2018

Identifiers

DOI

10.1002/EJI.201646583

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27873300%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

1 reference